Details of the Drug Combination

General Information of Drug Combination (ID: DCVNHGU)

Drug Combination Name
GDC-0068 Cotellic
Indication
Disease Entry Status REF
Embryonal rhabdomyosarcoma Investigative [1]
Component Drugs GDC-0068   DMWBZJD Cotellic   DMF9M57
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: CTR
Zero Interaction Potency (ZIP) Score: 14.454
Bliss Independence Score: 14.436
Loewe Additivity Score: 6.708
LHighest Single Agent (HSA) Score: 7.879

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of GDC-0068
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Phase 3 [2]
Colorectal cancer 2B91.Z Phase 3 [2]
Prostate cancer 2C82.0 Phase 3 [3]
Gastric adenocarcinoma 2B72 Phase 2 [4]
Solid tumour/cancer 2A00-2F9Z Phase 2 [5]
GDC-0068 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
RAC-alpha serine/threonine-protein kinase (AKT1) TTWTSCV AKT1_HUMAN Inhibitor [2]
------------------------------------------------------------------------------------
GDC-0068 Interacts with 3 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Phosphorylation [8]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Increases Response To Substance [8]
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Affects Response To Substance [8]
------------------------------------------------------------------------------------
Indication(s) of Cotellic
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 3 [6]
Breast cancer 2C60-2C65 Phase 2 [2]
Head and neck cancer 2D42 Phase 1 [2]
Renal cell carcinoma 2C90 Phase 1 [2]
Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
Urothelial carcinoma 2C92.0 Phase 1 [2]

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Embryonal rhabdomyosarcoma DCUJIAF Rh36 Investigative [1]
Embryonal rhabdomyosarcoma DC7FFBO RD Investigative [1]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of Roche.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031868)
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 ClinicalTrials.gov (NCT01106599) A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health.
8 PI3K/AKT inhibitors aggravate death receptor-mediated hepatocyte apoptosis and liver injury. Toxicol Appl Pharmacol. 2019 Oct 15;381:114729. doi: 10.1016/j.taap.2019.114729. Epub 2019 Aug 22.